TAVR Researchers Look To Lower-Risk Patients, Less Data Demands
This article was originally published in The Gray Sheet
Edwards Lifesciences' Sapien 3 valve looked good at the annual American College of Cardiology conference, including in intermediate-risk patients. Could it mean less follow-up demands for future approvals? Meanwhile, Medtronic continued to press its status as the only company with a TAVR device shown superior to surgery.